Combination Therapy Empagliflozin and metformin are frequently combined
The formulation does not contain synthetic GLP-1 but is designed to facilitate the bodys ability to manage appetite and maintain energy levels
It is not a controlled substance for the general public in the way a scheduled drug is, but it also holds no legal therapeutic-use status, which is why its sold strictly as a research compound rather than a consumer product
J Inorg Biochem 195:111
Liepinsh E, Makrecka-Kuka M, Volska K, Kuka J, Makarova E, Antone U, et al
"Rather than compete on the merits of its products, Novo is asking a court to stop Lilly from communicating the results of that trial," the spokesperson said